Distribution of carbamazepine and its metabolites carbamazepine-10,11-epoxide and iminostilbene in body fluids and organ tissues in five autopsy cases

被引:0
|
作者
Tatsunori Takayasu
Yuko Ishida
Akihiko Kimura
Mizuho Nosaka
Yumi Kuninaka
Mariko Kawaguchi
Toshikazu Kondo
机构
[1] Kanazawa University,Department of Forensic and Social Environmental Medicine, Division of Environmental Science, Graduate School of Medical Science
[2] Wakayama Medical University,Department of Forensic Medicine
来源
Forensic Toxicology | 2010年 / 28卷
关键词
Carbamazepine; Carbamazepine-10,11-epoxide; Iminostilbene; GC-MS; Tissue distribution; Human;
D O I
暂无
中图分类号
学科分类号
摘要
Carbamazepine (CMZ) and its metabolites, carbamazepine-10,11-epoxide (CMZepo) and 2,2’-iminostilbene (Imi), were simultaneously assayed by gas chromatography-mass spectrometry (GC-MS) in body fluids and organ tissues taken from victims in five autopsy cases. Clomipramine-HCl was added to each specimen as internal standard (IS); target compounds and IS were simultaneously extracted with an Extrelut NT column before analysis by GC-MS. The concentrations of CMZ were generally much higher in organ tissues than in blood and urine, and were higher in the liver than in the lung in three cases. The concentrations of metabolites CMZepo and Imi were lower than those of CMZ in all body fl uid and organ tissue specimens; the Imi concentrations in the brain were higher than CMZepo concentrations in four cases. Imi concentrations in the kidney, however, were lower than those of CMZepo in four cases. In the lung and liver, the concentrations of Imi did not show a consistent trend; those of Imi were higher or lower than those of CMZepo, but both metabolites were not at negligible levels. To our knowledge, this is the fi rst demonstration of the distribution of Imi among human body fluids and tissues.
引用
收藏
页码:124 / 128
页数:4
相关论文
共 50 条
  • [41] SINGLE-DOSE KINETICS AND METABOLISM OF CARBAMAZEPINE-10,11-EPOXIDE
    TOMSON, T
    TYBRING, G
    BERTILSSON, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (01) : 58 - 65
  • [42] INVESTIGATION OF CARBAMAZEPINE-10,11-EPOXIDE DURING LAMOTRIGINE TREATMENT IN CHILDREN
    ERIKSSON, AS
    NERGARDH, A
    BOREUS, L
    EPILEPSIA, 1995, 36 : S162 - S162
  • [43] SEIZURE EXACERBATION AND STATUS EPILEPTICUS RELATED TO CARBAMAZEPINE-10,11-EPOXIDE
    SO, EL
    RUGGLES, KH
    CASCINO, GD
    AHMANN, PA
    WEATHERFORD, KW
    ANNALS OF NEUROLOGY, 1994, 35 (06) : 743 - 746
  • [44] INDUCTION EFFECT OF PHENOBARBITAL ON THE CARBAMAZEPINE TO CARBAMAZEPINE-10,11-EPOXIDE PATHWAY IN RHESUS-MONKEYS
    PATEL, IH
    WEDLUND, P
    LEVY, RH
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1981, 217 (03): : 555 - 558
  • [45] IDENTIFICATION OF A REARRANGED DEGRADATION PRODUCT FROM CARBAMAZEPINE-10,11-EPOXIDE
    BAKER, KM
    FRIGERIO, A
    MORSELLI, PL
    PIFFERI, G
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1973, 62 (03) : 475 - 476
  • [46] FLUCTUATIONS IN SALIVARY CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE CONCENTRATIONS DURING THE DAY IN EPILEPTIC CHILDREN
    PAXTON, JW
    AMAN, MG
    WERRY, JS
    EPILEPSIA, 1983, 24 (06) : 716 - 724
  • [47] THE DIURNAL-VARIATION OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE CONCENTRATION OF SALIVA IN CHILDREN WITH EPILEPSY
    EEGOLOFSSON, O
    BACKMAN, E
    BERTLER, A
    DAHLSTROM, G
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1985, 12 (02) : 173 - 173
  • [48] CARBAMAZEPINE THERAPY FOR AGGRESSIVE-BEHAVIOR IN CHILDHOOD - THE RELATIONSHIP OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE CONCENTRATIONS TO RESPONSE
    SAKLAD, JJ
    JUSTER, C
    ATKINSON, S
    COHEN, M
    MOORE, E
    QUANDT, C
    PHARMACOTHERAPY, 1988, 8 (02): : 136 - 136
  • [49] POTENT THERAPEUTIC EFFECT OF CARBAMAZEPINE-10,11-EPOXIDE IN TRIGEMINAL NEURALGIA
    TOMSON, T
    BERTILSSON, L
    ARCHIVES OF NEUROLOGY, 1984, 41 (06) : 598 - 601
  • [50] Determination of carbamazepine and its metabolite carbamazepine-10,11-epoxide in serum with gas-chromatography mass spectrometry
    Minkova, G
    Getova, D
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2001, 23 (09): : 481 - 485